Sign In
Buy DGX
$233.72
+1.77 (+0.763%)
At Close: Aug 04, 2026
QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View
04:57pm, Friday, 05'th Aug 2022 Zacks Investment Research
QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.
AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates
04:56pm, Friday, 05'th Aug 2022 Zacks Investment Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.
Myriad Genetics (MYGN) Q2 Earnings Top, Gross Margin Down
04:01pm, Friday, 05'th Aug 2022 Zacks Investment Research
Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.
Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips
01:40pm, Friday, 05'th Aug 2022 Zacks Investment Research
Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View
05:37pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.
Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down
05:32pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.
PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag
04:30pm, Thursday, 04'th Aug 2022 Zacks Investment Research
PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.
BD (BDX) Beats on Q3 Earnings and Revenues, Raises FY22 View
04:28pm, Thursday, 04'th Aug 2022 Zacks Investment Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.
Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down
04:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
These 3 Companies Are Taking on Monkeypox
02:37pm, Thursday, 04'th Aug 2022 The Motley Fool
A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.
Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut
12:40pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.
These 3 Companies Are Taking on Monkeypox
10:37am, Thursday, 04'th Aug 2022
A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.
CVS Health (CVS) Q2 Earnings Beat Estimates, Margins Down
04:30pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
CVS Health (CVS) posts better-than-expected results in Q2, with robust performances across all operating segments driving the top line.
Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down
04:17pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.
Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut
02:27pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.
